A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Over the past two decades, the immune system has attracted increasing attention for its role in fighting cancer. As researchers have learned more and more about the cancer-immune system interplay, ...

CRISPR has a problem: an embarrassment of riches. Ever since the gene editing system rocketed to fame, scientists have been looking for variants with better precision and accuracy. One search method ...

Like the find-and-replace feature of a word processor, CRISPR-based engineering allows scientists to quickly and efficiently edit DNA sequences with base pair precision. Lauded as the great ...

The colonies of Escherichia coli sitting in this petri dish become pathogenic when they carry Shiga toxin genes. Credit: Shutterstock “We’re essentially converting a pathogenic strain into a ...

CRISPR Therapeutics AG (CRSP ... As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...